Continuing Medical Education Series
Advances and Updates in Urologic Oncology
Register for the SeriesJoin us for our virtual didactic lecture series on critical topics and innovations in genitourinary oncology.
Earn one AMA PRA Category 1 Credit(s)™ is available per session.
Led by Ashley E. Ross, MD, PhD, the conference takes place the third Thursday of the month following GU Oncology Conference at 5:30 pm CST. Dr. Ross is a surgeon-scientist at Northwestern University Feinberg School of Medicine and member of Robert H. Lurie Comprehensive Cancer Center at Northwestern University who specializes in urology and urologic oncology, and is a nationally recognized expert in prostate cancer.
Video Archive
Hypofractionated Radiation Treatment for Treatment of Prostate Cancer
Northwestern Medicine Radiation Oncologists, William Hartsell, MD, Nasir Mohammed, MD, MBA, Stephen Mihalcik, MD, PhD, and Adil Akthar, MD, discuss fractionation of radiation therapy treatment in prostate cancer.
Management of Recurring Prostate Cancer: Can Radiation Help?
Sean Sachdev, Assistant Professor of Radiation Oncology at the Feinberg School of Medicine at Northwestern University, discusses the use of radiation for the management of recurring prostate cancer.
PI3K/Akt Pathway Inhibition for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
David VanderWeele, MD, PhD, Assistant Professor of Medicine (Hematology and Oncology) at Northwestern University Feinberg School of Medicine, discusses the PI3K/AKT pathway and its role in cancer, PI3K/AKT pathway alterations in prostate cancer, and inhibitors of the pathway and recent clinical trial results.
Small Molecule MYC Inhibitors for Cancer Therapy
Sarki Abdulkadir, MD, PhD, discusses his research on the MYC protein and its role in cancer treatment.
Updates on Management of Metastatic Hormone-Sensitive Prostate Cancer
Alicia Morgans, MD, MPH, discusses management options for patients with metastatic hormone-sensitive prostate cancer.
Bladder Cancer: Best of Journals
Shilajit Kundu, MD and Joshua Meeks, MD, PhD, discuss practice changing articles in bladder cancer.
Non-Radical Treatments for Prostate Cancer
Ashley Ross, MD, PhD, reviews sub-total glad therapies for prostate cancer, including patient selection and considerations, treatment selection and outcomes.
Enhancing Minority Recruitment and Participation in Clinical Trials
Adam Murphy, MD, MBS, MSCI, Assistant Professor of Urology, reviews factors that may influence minority recruitment and participation in clinical trials and presents strategies for increasing diversity in clinical trials.
Highlights in Urologic Oncology from ASCO 2021
David VanderWeele, MD, PhD, Assistant Professor of Medicine in Hematology/Oncology, reviews the clinical and translational GU oncology research presented during the 2021 ASCO annual meeting.
Prostate Biopsy Techniques: Ways to Optimize Cancer Detection and Ensure Patient Safety
Drs. Edward Schaeffer and Matthew Allaway discuss tools for optimizing prostate biopsy to enhance detection of clinically significant cancer and strategies to reduce morbidity for patients undergoing prostate biopsy.
Association of Inflammatory Bowel Disease and Prostate Cancer
Shilajit Kundu, MD, Professor of Urology at Northwestern Medicine describes the physiologic and genetic link between gut inflammation and prostate cancer risk, and potential targets that may be used in mitigating risk of inflammation induced tumorigenesis of the prostate.
Salvage Treatment for Prostate Cancer
Ashley Ross, MD, Professor of Urology at Northwestern Medicine discusses treatment plans for recurring prostate cancer also called second-line or salvage treatment.
PET Imaging in Prostate Cancer
Hatice Savas, MD, Assistant Professor of Radiology, discusses current PET radiotracers that are used in prostate cancer imaging and newly approved PSME PET tracers.
Is there still a role for docetaxel in mHSPC?
Sweeney Christopher, MBBS, Medical Oncologist at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School describes treatment selections in metastatic hormone-sensitive prostate cancer (mHSPC).
Implementation of Smoking Cessation in Urologic Oncology Practice
Richard Matulewicz, MD, MSCI, MS, Urologic Oncologist at Memorial Sloan Kettering Cancer Center (MSKCC) and Assistant Professor at Weill Cornell Medical College, explains how cigarette smoking is associated with several genitourinary disease processes, but is most causally linked with bladder cancer.
Robotic Reconstruction of Complications in Urologic Oncology
Ziho Lee, MD, Assistant Professor of Urology at Northwestern Medicine discuss the contemporary use of robotic assistance in the treatment of complications following urologic oncologic procedures.
Prostate Cancer for Gay and Bisexual Men
Channa Amarasekera, MD, Assistant Professor of Urology at Northwestern University Feinberg School of Medicine, discusses the emerging medical and public health concern of prostate cancer in gay, bisexual, and other men who have sex with men (GBM).
Highlights in Urologic Oncology from ASCO 2022
David VanderWeele, MD, PhD, Assistant Professor of Medicine in Hematology/Oncology, reviews the clinical and translational GU oncology research presented during the 2022 ASCO annual meeting.
Computational Pathology and The Future of Diagnosis
Lee Cooper, PhD, Associate Professor & Director of Computational Pathology at Northwestern Medicine, uncover the potential of computational pathology & how it can help bring about a precision diagnosis future.
Rational Treatment of HRR-Deficient Prostate Cancer
Emmanuel S. Antonarakis, MD, Clark Endowed Professor of Medicine and Director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation (HOT) of the University of Minnesota Medical School assesses the treatment options for Homologous Recombination Repair (HRR)-deficient prostate cancer.
The Role of Partial Nephrectomy in the Management of Wilms Tumor.
Edward Gong, MD, Pediatric Urologist at Ann & Robert H. Lurie Children's Hospital of Chicago describes how partial nephrectomies may be an viable surgical option for Wilms Tumor.
Optimizing Retroperitoneal Lymph Node Dissection (RPLND); Anatomic and Technical Considerations
Joel Sheinfeld, MD, Florence &Theodore Baumritter/ Enid Ancell Chair of Urologic Oncology, Vice-Chairman/ Deputy Chief of Urology at Memorial Sloan Kettering Cancer Center (MSKCC) and Program Director of the Urology Fellowship, describes the complex neurovascular relationships that are crucial to performing a successful nerve-sparing retroperitoneal lymph node dissection (RPLND), as well as surgical techniques.
Penile Cancer Update 2022
Curtis A. Pettaway, MD, Professor of Urology at The University of Texas MD Anderson Cancer Center in Houston Texas, shares keys updates in the management of penile cancer.
Harnessing Endothelial Properties to Block Metastasis
Luisa Iruela-Arispe, PhD, Chair of the Department of Cell and Developmental Biology, Stephen Walter Ranson Professor of Cell Biology Professor of Cell and Developmental Biology at Northwestern University Feinberg School of Medicine, describes the different roles of the endothelium in the process of metastasis formation and how that can be harnessed to block metastasis.
Stereotactic Radiotherapy (SABR/SBRT) for Prostate Cancer: Present and Future
Sean Sachdev, MD, Assistant Professor of Radiation Oncology at Northwestern University Feinberg School of Medicine discusses the adavancements of the rapidly emerging modality for the treatment of localized prostate cancer; Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) and how the recently advances in radiation delivery technology is creating an effective, safe, and highly convenient form of curative therapy.
Multiparametric MRI of the Prostate: Biopsy Risk Calculators and Surgical Implications
Hiten D. Patel, MD, MPH, Assistant Professor of Urology at the Northwestern University Feinberg School of Medicine discusses the changes in prostate cancer risk prediction with Multiparametric MRI (mpMRI) to detect clinically significant PCa and reviews studies supporting use of mpMRI prior to prostate biopsy.
Biomarker-Guided Neoadjuvant Therapy for Bladder Cancer
David J. McConkey, Ph.D, inaugural director of the Johns Hopkins Greenberg Bladder Cancer Institute, Professor in the Department of Urology at Johns Hopkins Medicine, and The Erwin and Stephanie Greenberg Professor of Urology at the James Buchanan Brady Urological Institute, explains the current status of predictive biomarkers for patient selection for neoadjuvant chemotherapy and discusses how DNA damage repair mutations affect the response to neoadjuvant chemotherapy.
Advanced Kidney Cancer: What the Urologist Needs to Know
Hyung L. Kim, MD a renowned academic urologist and associate director of surgical research at the Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai, discusses the latest and most promising treatment options for urological cancers. Dr. Kim provides a comprehensive overview of the most innovative surgical procedures, targeted therapies and immunotherapies that are emerging as more effective treatments for urological cancers. This video provides an insightful discussion of the most advanced and effective treatment options for urological cancers, helping patients and medical professionals stay informed and up-to-date on the most promising treatment options available.
Current and Emerging Applications of PSMA PET
Steven Patrick Rowe, M.D., Ph.D, Associate Professor of Radiology and Radiological Science at Johns Hopkins University, shares insights into the current and emerging applications of PSMA-targeted PET. Dr. Rowe highlights imaging of non-prostate cancers, the use of advanced quantitative analysis, and response assessment. With his expertise, he offers a comprehensive overview of the latest updates in PSMA-targeted PET imaging, making it a valuable watch for healthcare professionals, researchers, and students interested in the field.
Diagnostic Biomarkers of Prostate Cancer in 2023 and Beyond
Jeffrey J. Tosoian, MD, MPH, Assistant Professor of Urology at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, sheds light on the critical role of cancer biomarkers and measures of clinical performance in the diagnosis of prostate cancer. Dr. Tosoian provides a thorough review of clinically-applicable literature characterizing the performance of currently-available diagnostic biomarkers for prostate cancer. He also delves into the development and validation of a novel prostate cancer biomarker that specifically targets higher-grade cancers, offering promising possibilities for improved diagnosis and treatment. This engaging presentation is a must-watch for anyone interested in the advancements and potential impact of biomarkers in the field of prostate cancer diagnosis.
Prostate Cancer in Gay and Bisexual Men: The Intersectional Racial-Sexual Minority Experience
If you missed the live webinar, don't worry, we've got you covered. This groundbreaking webinar brought together patient advocates, prostate cancer experts, and health disparity experts to discuss the unique challenges that gay and bisexual men face when it comes to prostate cancer. This webinar explored how the compounding effect of intersectional racial and sexual minority status plays into the experience of African American Gay and Bisexual Men with prostate cancer care. Dr. Channa Amarasekera is the director of the Gay and Bisexual Men's Urology Program, Dr. Adam Murphy is an Assistant Professor of Urology and Preventive Medicine (Cancer Epidemiology and Prevention), Robert Watkins, a prostate cancer survivor, is a patient expert who provided insight from the perspective of an African American Gay man navigating prostate cancer. Moderated by Dr. Chad Achenbach, associate professor of medicine and infectious diseases at Northwestern University in the Feinberg School of Medicine. Together, they provided invaluable insights into prostate cancer screening and treatment for gay and bisexual men. The topics covered included the latest research on prostate cancer in gay and bisexual men and African American men, the importance of early detection, and the role of genetics in prostate cancer risk. One of the key takeaways from the webinar was the importance of tailored prostate cancer screening and treatment for gay and bisexual men. The experts emphasized that there is no one-size-fits-all approach to prostate cancer care, and that it's essential to consider the unique needs and experiences of sexual and racial minority patients. The experts provided insights into why disparities in prostate cancer care exist and what can be done to address them.
SUO22 Highlights
Hiten Patel, MD, MPH, Assistant Professor of Urology at the Northwestern University Feinberg School of Medicine reviews highlights from the 23rd annual meeting of the Society of Urologic Oncology Conference.
Management of Testis Cancer
Presented by the Polsky Urologic Cancer Institute at Northwestern Medicine, "Advances and Updates in Urologic Oncology" is a virtual didactic lecture series on critical topics and innovations in genitourinary oncology. In this video, Sia Daneshmand, MD, Professor of Urology and Director of Clinical Research at the University of Southern California, discusses the current management of testis cancer.
Prostate Cancer A Year in Review and the Year to Come
Ashley Ross, MD, PhD, Associate Professor of Urology and Clinical Director for the Polsky Institute at Northwestern Feinberg School of Medicine, highlighting updates in prostate cancer diagnosis and care from the year 2023 and provide insights into what to expect in the future. In this video, Dr. Ross takes you on a direct journey into the world of medical innovation, unveiling breakthrough technologies and innovative strategies that have recently emerged. He also extends his expertise to offer a forward-looking perspective into the future of prostate cancer care. What groundbreaking developments are on the horizon? How will technology and research continue to shape the urology landscape? Get ready for a sneak peek into the thrilling possibilities that lie ahead in the ever-evolving field of prostate cancer diagnosis and treatment.